Skip to content

Prospective cohort study on infections and their prophylaxis after splenectomy

Prospective cohort study on infections and their prophylaxis after splenectomy - Asplenie-Studie

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00004332
Enrollment
1000
Registered
2012-08-24
Start date
2012-09-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D73.0 A41.9

Interventions

Group 1: At baseline, the following parameters will be documented: - demography (age, sex, body weight, body height) - indication for splenectomy - Charlson's comorbiditiy index and selected other

Sponsors

Universitätsklinikum FreiburgCentrum für chronische Immundefizienz (CCI)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients after splenectomy no documented spleen on imaging studies Hypo- or asplenia (Howell-Jolly-Bodies present)

Exclusion criteria

Exclusion criteria: no informed consent

Design outcomes

Primary

MeasureTime frame
Number and timing of infections requiring hospitalization after splenectomy

Secondary

MeasureTime frame
•Number and timing of Infections requiring intensive care therapy after splenectomy •Causal pathogen, focus of infection •Total mortality and mortality due to infection after splenectomy •Timing and type of required vaccination after splenectomy •Antibiotic prophylaxis •Concurrent or previous antineoplastic chemotherapy or immunosuppressive medication •other risk factors for infection (age, sex, smoking, alcohol, body weight)

Countries

Germany

Contacts

Public ContactSiegbert Rieg

Centrum für Chronische Immundefizienz (CCI) und Abteilung Infektiologie, Klinik für Innere Medizin II; Universitätsklinikum Freiburg

siegbert.rieg@uniklinik-freiburg.de+49 761 270 18190

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026